FORCE advocates for families facing hereditary breast and ovarian cancer in areas such as access to care, research funding, insurance, and privacy.

Advocacy > Issues > PSA Screening Guidelines Fall Short: High-Risk Men have Unique Needs

| More


FORCE joined over two dozen orgs in a statement on the final rule permitting expansion of association health plans. Read Statement...

FORCE staff are attending the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

We joined 80 patient advocacy, medical, and industry orgs in urging Congress to enact legislation to modernize FDA oversight of clinical laboratory diagnostics. Read letter...

FORCE, along with over 100 other organizations, is advocating for continued funding of DoD research programs. Read our letters to Senate and House leaders.

FORCE and over 100 patient and professional health orgs reached out to Congressional leaders to oppose expansion of short-term health insurance plans. Read letter...

PSA Screening Guidelines Fall Short: High-Risk Men have Unique Needs

Screening & Prevention


In May 2012, The United States Preventive Services Task Force (USPSTF) issued their recommended changes for prostate cancer screening in men. The draft guidelines recommended against PSA screening for men of any age. In response to the concerns submitted by FORCE that the guidelines might not apply to people with BRCA mutations, the USPSTF modified the guidelines to reflect this important detail. Read the full USPSTF Guidelines for Screening for Prostate Cancer.

FORCE contacted the USPSTF in response to the draft guideline changes and presented the following information:

Men with BRCA 2 mutations face:

  1. a lifetime risk for prostate cancer that is much higher than men in the general population and may be as high as 33%,
  2. prostate cancer risk at a younger age than the general population, and
  3. risk for more aggressive prostate cancers.

The USPSTF issued new prostate cancer screening guidelines on May 21, 2012.

  • The new USPSTF guidelines on prostate cancer screening recommend against screening in men of average risk for prostate cancer.
  • The USPSTF acknowledged that the guidelines do not apply to men with BRCA mutations.

The Task Force took our concerns about prostate cancer in men with BRCA mutations into account and added the following statement to their guidelines:

"This recommendation...does not consider PSA-based testing in men with known BRCA gene mutations who may be at increased risk for prostate cancer."

Search Policy Issues by Keyword

FORCE:Facing Our Risk of Cancer Empowered